Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
Summary
But he also pointed to moves the company has made to shore up its multiple sclerosis franchise and add drug candidates in other therapeutic areas. Novartis (NYSE: NVS ) reported that a patient with Type 1 SMA, the most severe form, died from sepsis in a European trial and that it was “possibly” related to treatment. —Gilead Sciences (NASDAQ: GILD ) reported that selonsertib, its experimental treatment for the fatty liver disease NASH, failed a second Phase 3 study . —Eli Lilly (NYSE: LLY ) announced top-line data showing its drug ixekizumab (Taltz) met the main goals of a late-stage study in axial spondyloarthritis, a chronic inflammatory disease. —Bausch Health (NYSE: BHC ) won the FDA nod for plaque psoriasis treatment Duobrii, a topical lotion that combines halobetasol proprionate and tazarotene.
Classifications
AskAI Classifications
LabelsLinked Companies
